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Influenza Coinfection: Be(a)ware 
of Invasive Aspergillosis
To the Editor—Uyeki et  al [1] re-
cently published the 2018 update of the 
clinical practice guideline regarding the 
diagnosis, chemoprophylaxis, and insti-
tutional outbreak management of sea-
sonal influenza. The document discusses 
several aspects related to influenza, in-
cluding the occurrence and management 
of coinfections. Although the guideline is 
primarily aimed to guide US clinicians, 
the recommendations are implemented 
in many countries worldwide. We 
therefore draw attention to recent 
observations regarding invasive aspergil-
losis as coinfection in patients with severe 
influenza in some regions [2]. Although 
the guideline states that invasive fungal 
coinfection is rare in adults with in-
fluenza, 3 cohort studies performed in 
Belgium and the Netherlands showed 
that influenza-associated aspergillosis 
(IAA) had occurred in 16%–23% of in-
fluenza patients in the intensive care unit 
(ICU) [3–5]. The largest cohort study 
investigated 7 ICUs over a period of 7 flu 
seasons and showed that influenza and 
the use of corticosteroids before ICU ad-
mission were independent risk factors for 
IAA [5]. IAA was observed in every flu 
season and both in patients with influ-
enza A  and influenza B pneumonia [5]. 
The mortality of severe influenza patients 
with IAA was 51% compared with 28% in 
those without IAA [5]. Furthermore, IAA 
coinfection occurred in patients with a 
broad variety of underlying conditions, 
and up to 30% of patients had been previ-
ously healthy [4, 5].
Influenza virus has been shown to 
cause ulceration of the tracheobronchial 
epithelium, thus providing an oppor-
tunity for Aspergillus to cause inva-
sive infection [6]. Indeed, up to 25% 
of patients with IAA present with 
Aspergillus tracheobronchitis, a mani-
festation of invasive aspergillosis where 
the infection is primarily confined to 
the tracheobronchial tree. Invasive 
Aspergillus tracheobronchitis is difficult 
to diagnose as the main radiologic fea-
ture is tracheal and bronchial thickening, 
and therefore visualization of epithelial 
plaques through bronchoscopy is the 
recommended diagnostic procedure [7].
The frequency of IAA may vary be-
tween geographic regions, but IAA 
cases have been reported in at least 16 
countries, including the United States 
[8, 9]. Furthermore, the epidemiology 
of IAA may be underestimated due to 
cases remaining undiagnosed since res-
piratory deterioration is considered 
to be caused by bacterial coinfection 
rather than fungal infection and appro-
priate diagnostics are not performed. 
International surveys are needed to inves-
tigate diagnostic procedures commonly 
used in influenza patients with suspected 
coinfection and to determine the fre-
quency of IAA. However, at this point, 
guidelines, such as the one published by 
Uyeki et al, should include the aforemen-
tioned observations to overcome lack of 
awareness of coinfection with Aspergillus 
in ICU patients with influenza.
Given the high mortality of IAA it 
is recommended to consider IAA as a 
possible cause of coinfection in adult 
patients with severe influenza irrespec-
tive of their underlying condition and to 
perform a diagnostic workup for inva-
sive aspergillosis, including bronchos-
copy and bronchoalveolar lavage (BAL) 
[10]. Microbiological analysis should 
include microscopy, fungal culture, and 
galactomannan testing of BAL and serum 
if BAL is not available. If any of these tests 
indicate the presence of Aspergillus, imme-
diate antifungal therapy is indicated. This 
approach will help to diagnose and treat 
patients with IAA early and to determine 
the true epidemiology of this coinfection.
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Reply to Verweij et al
To the Editor—We agree with Verweij 
et  al [1] that invasive pulmonary asper-
gillosis (IPA) is a complication reported 
in severely ill influenza patients and that 
clinicians caring for influenza patients, 
particularly immunocompromised per-
sons, should be aware of the potential 
for IPA. The Infectious Diseases Society 
of America’s influenza guidelines listed 
fungal coinfection as a complication 
in Table 3 [2]. The guidelines included 
studies published through January 2018 
[2], so we were unable to include re-
cent reports of IPA in intensive care unit 
(ICU) patients in the Netherlands and 
Belgium [3].
To date, IPA does not appear to 
be a common influenza complica-
tion in North America, the target au-
dience for the guidelines. IPA might 
be underdetected in regions where 
it has not been studied as intensively 
as in the Netherlands and Belgium 
[3]. We are unaware of prospective 
population-based surveillance data 
for influenza-associated IPA in North 
America. Nevertheless, the population 
at highest risk for IPA and most likely 
to undergo appropriate fungal studies 
are hematopoietic stem cell transplant 
(HSCT) and solid organ transplant 
recipients, particularly lung transplant 
recipients. However, in a prospective 
5-year cohort of 616 HSCT recipients 
with influenza in the United States, 
Canada, and Spain, only 2 patients 
(0.3%) had cultured-confirmed IPA, 
and neither were hospitalized [4]. Data 
on serum or bronchoalveolar lavage 
(BAL) galactomannan testing were not 
collected, but it is unlikely that many 
IPA cases were missed as patients were 
monitored for 28  days for evidence of 
complications [4]. Furthermore, a pro-
spective 5-year surveillance study of 437 
HSCT recipients in Seattle, Washington, 
reported that respiratory syncytial virus 
and adenovirus upper respiratory tract 
infections, but not influenza A  virus, 
and detection of any respiratory virus in 
BAL fluid, were significantly associated 
with IPA [5].
Although data are incomplete, there 
appears to be substantial geographic var-
iation in the frequency of IPA identified 
in critically ill influenza patients. Many 
of the Dutch and Belgian patients were 
diagnosed with IPA soon after ICU ad-
mission, suggesting that they may have 
become colonized with Aspergillus in the 
community [3]. One possibility is that 
the high frequency of IPA reported in 
the Netherlands and Belgium [3] reflects 
greater environmental exposure to 
Aspergillus. Corticosteroids also appear 
to be a potential risk factor for possible or 
probable IPA (corticosteroid use in 56% 
with IPA vs 29% without [P < .001]) [3]; 
this association was also reported in an-
other study [6]. Because evidence shows 
that corticosteroid use likely increases 
mortality in influenza patients, these 
data further support recommendations 
to avoid corticosteroids for treatment of 
influenza [2].
Clinicians should be cognizant of 
the risk of IPA in critically ill patients, 
particularly immunocompromised 
patients or those receiving corticosteroids. 
Except where IPA prevalence is reported 
to be high, we disagree with Verweij et al 
that diagnostic evaluation for IPA, in-
cluding bronchoscopy and BAL, should 
be routinely performed regardless of un-
derlying condition in adult patients with 
severe influenza [1]. The sensitivity and 
specificity of galactomannan testing out-
side of HSCT recipients is unknown and 
results should be interpreted with caution 
[7]. Rather, studies to understand the in-
cidence, risk factors, and clinical features 
of IPA in influenza patients are needed 
worldwide.
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